Blog

Jennifer Buell: Thrilled to share MiNK Therapeutics’ groundbreaking work at SITC 2024

Jennifer Buell/LinkedIn

Nov 14, 2024, 00:24

Jennifer Buell: Thrilled to share MiNK Therapeutics’ groundbreaking work at SITC 2024

Jennifer Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post on LinkedIn by

“Standing with the team and thrilled to share MiNK Therapeutics’ groundbreaking work at SITC 2024! Paul Ibbett presented our innovative PRAME-TCR iNKT cell therapy at Poster #374.

This therapy represents the next generation of cell therapy—an allogeneic, gene-editing-free platform designed to overcome the challenges of T-cell exclusion, exhaustion, and persistence, while targeting solid tumors like NSCLC, ovarian cancer, melanoma, and sarcoma. Proud of our team’s dedication to redefining precision and scalability in immunotherapy.”

Quoting

“The next generation of targeted cell therapy for solid tumors must be able to overcome barriers associated with T-cell exclusion, exhaustion and persistence, while being precise and scalable.

At SITC 2024, visit Poster #374 today, where Paul Ibbett presents MiNK Therapeutics innovative PRAME-TCR iNKT cell therapy. This allogeneic, off-the-shelf platform combines the unique advantages of iNKT cells with PRAME targeting, offering a gene-editing-free solution for challenging solid tumors like NSCLC, ovarian cancer, melanoma and sarcoma.”

More posts featuring Jennifer Buell.

Jennifer Buell is the President and Chief Executive Officer of MiNK Therapeutics and the executive council at Agenus. She is also on the Board of Directors at Agenus. She has over 25 years of experience, primarily focused on advancing therapies from discovery to commercialization.

Before her role at MiNK Therapeutics, Dr. Buell was the President and Chief Operating Officer at Agenus. Dr. Buell’s career also includes significant roles in research and development at Bristol-Myers Squibb and the Harvard Clinical Research Institute (Baim).

Dhan Chand, Ph.D., is Vice President of Research at Agenus, focusing on cancer immunology, immunotherapy, and cell and molecular biology. Previously, he served as a Graduate Research Assistant and Project Co-Leader in the Department of Cell and Systems Biology at the University of Toronto.